UNIVERSITY OF WASHINGTON

- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1861-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
1.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1193 trials with phase data)β’ Click on a phase to view related trials
The Effective of Immersive Virtual Reality Distraction on Memory: Study 1
- Conditions
- Healthy Participants
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 16
- Registration Number
- NCT07172230
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
- Conditions
- Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm
- Interventions
- Other: Survey AdministrationProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 27
- Registration Number
- NCT07148947
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Integrating HIV Prevention With TB Household Contact Evaluation in Uganda
- Conditions
- Tuberculosis (TB)Human Immunodeficiency Virus (HIV) Prophylaxis
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 2480
- Registration Number
- NCT07119359
- Locations
- πΊπ¬
Infectious Diseases Institute, Kampala, Uganda
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineProcedure: Computed TomographyDrug: Cyclin-Dependent Kinase 4 InhibitorDrug: Cyclin-Dependent Kinase 6 InhibitorProcedure: Positron Emission TomographyProcedure: Ultrasound ImagingProcedure: Biopsy ProcedureProcedure: Biospecimen Collection
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 40
- Registration Number
- NCT07112053
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
- Conditions
- HIVHeart Failure
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT07105007
- Locations
- πΊπΈ
University of Washington, Seattle, Washington, United States
π§π·Londrina State University, Londrina, Parana, Brazil
- Prev
- 1
- 2
- 3
- 4
- 5
- 272
- Next
News
Lila Biologics Partners with Eli Lilly for AI-Driven Radioligand Therapy Development
Lila Biologics announced a global licensing and multi-target research collaboration with Eli Lilly focused on discovering and developing novel radioligand therapies for solid tumor imaging and treatment.
Novel Buprenorphine Protocol Eliminates Withdrawal Requirement for Opioid-Use Disorder Treatment
University of Washington researchers developed a new buprenorphine treatment protocol that allows patients to begin opioid-use disorder therapy without stopping fentanyl use or experiencing withdrawal symptoms.
Global Rheumatoid Arthritis Incidence Rises 13.2% Over Three Decades Despite Declining Mortality
Global rheumatoid arthritis incidence increased 13.2% from 1990 to 2021, affecting 17.9 million people worldwide by 2021, with significant regional disparities and a shift toward younger age groups.
Global Study Reveals Significant Gender Disparities in Health Outcomes
Men experience higher mortality rates from 13 of the top 20 global health conditions, with COVID-19 and heart disease showing 45% higher illness and death rates compared to women.
Stanford Researchers Develop Novel RNA Blood Test for Cancer Detection and Treatment Resistance Monitoring
Stanford Medicine researchers have developed a revolutionary blood test that analyzes cell-free RNA molecules to detect cancers at various stages, including early-stage lung cancer with 73% accuracy.
Breakthrough Diagnostic Tools for Early Fatty Liver Disease Detection: AI and Blood Tests Show Promise
New AI technology developed at University of Washington has identified hundreds of undiagnosed fatty liver disease cases by analyzing existing imaging scans, with 83% of patients with evidence of the disease lacking formal diagnosis.
Environmental Pollutants Significantly Increase Childhood Asthma Risk, New Studies Reveal
Recent research shows that ozone pollution exposure during a child's first two years increases asthma risk by 31% at ages 4-6, highlighting the need for long-term ozone regulation.
Wildfire Smoke Exposure Linked to Increased Dementia and Mental Health Risks, Studies Find
New research from Kaiser Permanente Southern California reveals wildfire smoke exposure significantly increases dementia risk, with each one-microgram-per-square-meter increase in wildfire-generated PM 2.5 associated with an 18% higher risk of dementia diagnosis.
Global Obesity Crisis Accelerating: 80% of Americans Projected to be Overweight or Obese by 2050
Four out of five Americans are projected to be overweight or obese by 2050, with obesity rates increasing faster than overweight, according to a comprehensive study published in The Lancet.
Experts Challenge Conventional Wisdom on Drug Launch Pricing Evaluations
New research identifies four critical limitations in comparing drug launch prices with value-based prices derived from conventional cost-effectiveness analyses, complicating policy decisions.